Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serio Invaio ...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
The latest update is out from Foghorn Therapeutics ( (FHTX) ).
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...
Hosted on MSN1mon
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?Foghorn Therapeutics Inc. (FHTX) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than ...
Short interest in Foghorn Therapeutics Inc (NASDAQ:FHTX) increased during the last reporting period, rising from 1.20M to 1.33M. This put 3.18% of the company's publicly available shares short.
By way of example, Foghorn Therapeutics (NASDAQ:FHTX) has seen its share price rise 156% over the last year, delighting many shareholders. But while history lauds those rare successes, those that fail ...
Nov. 04, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback